Photo Source: mii.mosreg.ru
The RPET radiochemical facility from R-Atom enterprise represents an integrated system for the complete radiopharmaceutical production cycle, medications containing radioactive isotopes administered to patients prior to PET/CT scanning for tumor visualization.
The facility will include a cyclotron for producing short-lived isotopes (primarily fluorine-18 with a 109.7-minute half-life), automated radiopharmaceutical synthesis modules, radiation shielding enclosures, and quality control equipment compliant with Good Manufacturing Practice (GMP) standards. Production will be located at the "Radiotherapeutic Equipment Factory" facility (part of R-Pharm Group) in the Dubna special economic zone.
Establishing proprietary radiochemical facilities is critically important for PET diagnostics development in regional centers. Fluorine-18's short half-life renders radiopharmaceutical delivery impossible over distances exceeding 200-300 km, the isotope must be produced and utilized within 2-3 hours. Currently, PET centers without onsite production receive radiopharmaceuticals from the nearest metropolitan areas.
In Russia, diagnostic radiopharmaceuticals, primarily 18F-FDG, a glucose molecule labeled with fluorine-18 isotope, are produced by Rosatom structures, federal medical centers and research institutions, as well as private laboratories, such as those operated by the PET-Technology network. Most radiopharmaceutical-producing centers currently utilize foreign equipment from GE Healthcare, Siemens Healthineers, and other manufacturers.
In Russia as of 2024, according to data from Rosatom and the Ministry of Health, over 100 PET scanners operated in state and private medical facilities. In 2025, Russia launched a specialized nuclear medicine development program, primarily focused on radionuclide diagnostics. According to program projections, in 2030 new SPECT departments will open in 26 regions, new PET/CT systems will be installed in 19 hospitals, and 18 existing PET/CT departments will receive equipment upgrades.
The number of diagnostic studies utilizing radiopharmaceuticals reached 1 million cases annually in Russia by 2025, of which approximately one-third represents PET/CT diagnostics.
Information regarding radiopharmaceutical application in Russia for diagnostics and therapy of oncologic malignancies can be accessed in Marus Media's special project.
Source: Moscow Region Government
All information on this website is provided for informational purposes only and does not constitute medical advice. All medical procedures require prior consultation with a licensed physician. Treatment outcomes may vary depending on individual characteristics. We do not guarantee any specific results. Always consult a medical professional before making any healthcare decisions.